PBLS Parabilis Medicines, Inc.
$25.03▲ +2.41%
Healthcare
Other
Volume 1.43M
Avg Volume (10D) 1.32M
Key Metrics & Fundamentals
Market Cap
$3.09B
P/E Ratio
–
Div Yield
0.00%
52W Range
22.66 - 42.49
% vs 50 MA
-26.11%
% vs 200 MA
–%
RSI-14
38.1
MACD Histogram
+0.0900
Beta (1Y vs SPY)
0.13
Free Cash Flow
-$4.24M
Gross Rev
$148,000
Gross Profit
$148,000
EBITDA
-$51.66M
COGS
–
Operating Exp
$51.03M
Operating Income
-$50.89M
EBIT
-$50.89M
Pretax Income
-$52.46M
Net Income
-$52.46M
EPS (Diluted)
-0.54
Price & Volume History
Loading chart…
Recent News
Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027
MarketBeat · Oct 24, 2026 5:02 PM ET
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
GlobeNewswire · Oct 24, 2026 8:45 AM ET
Parabilis Medicines (PBLS) Stock May Trade At A Premium Despite Fresh Zolucatetide Trial Updates
Simply Wall St. · Oct 20, 2026 4:06 PM ET
Parabilis Medicines (PBLS) Could Be 39% Undervalued As Zolucatetide Trial Expands
Simply Wall St. · Oct 20, 2026 3:12 PM ET
What Does Parabilis Medicines (PBLS) Expanding Zolucatetide Into FAP Mean?
Simply Wall St. · Oct 20, 2026 2:17 PM ET
Parabilis Soars 13% on Upcoming ESMO Data for “First-in-Class” Desmoid Tumor Drug
TIKR · Oct 19, 2026 1:30 PM ET
Parabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026
GlobeNewswire · Oct 19, 2026 7:00 AM ET
Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis
GlobeNewswire · Oct 14, 2026 7:00 AM ET
Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
PR Newswire · Oct 13, 2026 9:02 AM ET
Sixty Degree Capital Extends Its Track Record as Five Portfolio Companies Enter the Public Markets in 2026
CNW Group · Sep 28, 2026 10:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PBLS's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.